News, Scientific publications and Events

Gastroenterology Scientific Publication TASECTAN® XILAPLUS®

New scientific publication on Mucoprotection and diarrheal processes.

Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Clarifying the role of intestinal mucus in reducing inflammation and infection has led to the development of ‘mucosal protectors’. These agents form a bioprotective film in the gastrointestinal tract and potentially may prevent microorganisms from crossing the mucus barrier. To date, the most widely studied substances include xyloglucan (Xilaplus®) and gelatin tannate (Tasectan®, Gelenterum®). 2 new clinical studies are about to start to increase the body of evidence of those substances. Szajewska H, Kołodziej M, Łukasik J. Drug development and acute gastrointestinal infections. Expert Opin Investig Drugs. 2017 Dec 26:1-6

Gastroenterology Scientific Publication TASECTAN® DUO

New Scientific publication on TASECTAN® DUO

Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25.

Pathogenic microorganisms can adhere to the intestinal mucosa and influence cellular tight-junction function, leading to diarrhea. In an in vitro study, it was compared the protective efficacy of a combination of gelatine tannate plus inactivated probiotic (Tasectan® Duo) with that of other widely used antidiarrheal agents (Diosmectite, Saccharomyces boulardii, and a probiotic mixture). The study results clearly show that the protective efficacy of Tasectan® Duo manifests early and is maintained for 24 h. This effect is quicker and lasts longer that with the other compounds evaluated. These data further reinforce the potential broad utility of Tasectan® Duo in the management of diarrhea of several causes (e.g., infectious gastroenteritis, antibiotic therapy and chemotherapy) in population groups of all ages. Servi B, Ranzini F. Protective efficacy of antidiarrheal agents in a permeability model of Escherichia coli-infected CacoGoblet® cells. Future Microbiol. 2017 Oct 25. doi: 10.2217/fmb-2016-0195.

Gastroenterology News TASECTAN® DUO

Tasectan® Duo launched in Austria

We are pleased to announce the launch of Tasectan® Duo in Austria by our partner company Montavit. This will be Tasectan® Duo´s second market, after the successful introduction in Italy by Angelini. Tasectan Duo ® is the first combination of gelatin tannate and inactivated bacteria, and can be used to re-establish the physiological functions of the gut barrier, as well as to prevent dysbiosis. It is intended for prolonged diarrhea (lasting between 1 - 2 weeks) or for the prevention and management of diarrhea associated with antibiotic treatment, and is expected to capture part of the market space of probiotics used for diarrhea.